RecruitingPhase 3NCT03955445
Renal
Primary membranoproliferative glomerulonephritis
6
studies recruiting now
as of 7 Sept 2026
28
studies registered in total
as of 7 Sept 2026
29
countries with a recruiting site
as of 7 Sept 2026
5 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07746895
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
RecruitingPhase 3NCT05755386
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
RecruitingNot applicableNCT05996731
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
RecruitingPhase 2NCT04183101
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 6 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Primary membranoproliferative glomerulonephritis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Primary membranoproliferative glomerulonephritis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
5 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Rituximab (Blitzima)
Phase 3Iptacopan
Phase 3Cyclosporine (Capimune)
Phase 2Daratumumab (Daratumumab component of darzalex faspro)
Phase 2Eculizumab (Bekemv)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).